FDA Brief

Warning letters Drugs

FDA warning letter to

Trew Balance

High riskIssued Aug 25, 2025Posted Sep 2, 2025Center for Drug Evaluation and Research (CDER)

FDA warned Trew Balance that its Trew Vision CBD Eye Drops are an unapproved new drug sold with disease-treatment claims.

What happened

FDA reviewed the company's website at trewbalance.com in May 2025 and found a product page selling "Trew Vision CBD Eye Drops" with claims such as protecting from glaucoma and macular degeneration, and helping treat pink eye. FDA said the product is a drug because of those claims, is not generally recognized as safe and effective for those uses, and has no approved FDA application. The letter notes that eye products carry extra risk because they bypass some of the body's natural defenses.

What FDA found

  1. The website claims the eye drops prevent or treat diseases such as glaucoma, macular degeneration and pink eye, which makes the product a drug.

    Section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1)
  2. The product is not generally recognized as safe and effective for the uses claimed on the website, so it counts as a "new drug."

    Section 201(p) of the FD&C Act, 21 U.S.C. 321(p)
  3. There is no FDA-approved application for this product, so shipping it across state lines is illegal.

    Sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d)
  4. Labeling the product as homeopathic does not exempt it from the drug approval, adulteration or misbranding requirements.

    Section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1)

What FDA wants

Within fifteen working days, tell FDA in writing what steps you have taken to fix the violations and prevent them from recurring, or explain why you believe the product is not in violation. Send it to FDAAdvisory@fda.hhs.gov with the firm name and identifier 709880 in the subject line.

Who should pay attention

  • retailers and online marketplaces listing CBD eye drops
  • CBD and homeopathic product makers that make disease claims
  • brands selling ophthalmic products without FDA approval

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk